Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: A phase I trial of the Puget Sound Oncology Consortium

Gynecologic Oncology

Volumn 101, Issue 3, 2006, Pages 429-435

  Swisher, Elizabeth M ^a   Swensen, Ron E ^a   Greer, Benjamin ^a   Tamimi, Hisham ^a   Goff, Barbara A ^a   Garcia, Rochelle ^b   Koh, Wui jin ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cervix cancer; Chemoradiation; Clinical trial; Gemcitabine; Phase I

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LOW DRUG DOSE; LYMPHOCYTOPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE; RADIATION FIELD; TINNITUS; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; UTERINE CERVICAL NEOPLASMS;

EID: 33646567748     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.10.032     Document Type: Article

References (38)

1. Stehman F.B., Bundy B.N., DiSaia P.J., Keys H.M., Larson J.E., and Fowler W.C. Carcinoma of the cervix treated with radiation therapy: I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 67 (1991) 2776-2785
2. Perez C.A., Grigsby P.W., Chao K.S., Mutch D.G., and Lockett M.A. Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int. J. Radiat. Oncol. Biol. Phys. 41 (1998) 307-317
3. Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., Stevens R.E., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N. Engl. J. Med. 340 (1999) 1137-1143
4. Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 340 (1999) 1144-1153
5. Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., Hannigan E.V., Fowler Jr. W.C., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J. Clin. Oncol. 17 (1999) 1339-1348
6. Peters III W.A., Liu P.Y., Barrett II R.J., Stock R.J., Monk B.J., Berek J.S., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 18 (2000) 1606-1613
7. Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., Chafe W.E., Suggs III C.L., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Engl. J. Med. 340 (1999) 1154-1161
8. Rose P.G. Combined-modality therapy of locally advanced cervical cancer. J. Clin. Oncol. 21 (2003) 211-217
9. Shewach D.S., and Lawrence T.S. Radiosensitization of human solid tumor cell lines with gemcitabine. Semin. Oncol. 23 (1996) 65-71
10. Latz D., Fleckenstein K., Eble M., Blatter J., Wannenmacher M., and Weber K.J. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro. Int. J. Radiat. Oncol. Biol. Phys. 41 (1998) 875-882
11. Milas L., Fujii T., Hunter N., Elshaikh M., Mason K., Plunkett W., et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 59 (1999) 107-114
12. Pattaranutaporn P., Thirapakawong C., Chansilpa Y., Therasakvichya S., Ieumwananontachai N., and Thephamongkhol K. Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma. Gynecol. Oncol. 81 (2001) 404-407
13. Bergman A.M., Ruiz van Haperen V.W., Veerman G., Kuiper C.M., and Peters G.J. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin. Cancer Res. 2 (1996) 521-530
14. Peters G.J., Ruiz van Haperen V.W., Bergman A.M., Veerman G., Smitskamp-Wilms E., van Moorsel C.J., et al. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin. Oncol. 23 (1996) 16-24
15. Burnett A.F., Roman L.D., Garcia A.A., Muderspach L.I., Brader K.R., and Morrow C.P. A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix. Gynecol. Oncol. 76 (2000) 63-66
16. Duenas-Gonzalez A., Lopez-Graniel C., Gonzalez A., Reyes M., Mota A., Munoz D., et al. A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma. Ann. Oncol. 12 (2001) 541-547
17. Pearcey R., Brundage M., Drouin P., Jeffrey J., Johnston D., Lukka H., et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J. Clin. Oncol. 20 (2002) 966-972
18. Serkies K., and Jassem J. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity. Int. J. Radiat. Oncol. Biol. Phys. 60 (2004) 814-821
19. Villella J., Marchetti D., Odunsi K., Rodabaugh K., Driscoll D.L., and Lele S. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma. Gynecol. Oncol. 95 (2004) 539-545
20. Rademaker-Lakhai J.M., Crul M., Pluim D., Sparidans R.W., Baas P., Beijnen J.H., et al. Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Anti-Cancer Drugs 16 (2005) 1029-1036
21. Moufarij M.A., Phillips D.R., and Cullinane C. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol. Pharmacol. 63 (2003) 862-869
22. Blakley B.W., Gupta A.K., Myers S.F., and Schwan S. Risk factors for ototoxicity due to cisplatin. Arch. Otolaryngol. Head Neck Surg. 120 (1994) 541-546
23. de Jongh F.E., van Veen R.N., Veltman S.J., de Wit R., van der Burg M.E., van den Bent M.J., et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br. J. Cancer 88 (2003) 1199-1206
24. Zarba J.J., Jaremtchuk A.V., Gonzalez Jazey P., Keropian M., Castagnino R., Mina C., et al. A phase I-II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma. Ann. Oncol. 14 (2003) 1285-1290
25. Duenas-Gonzalez A., Cetina-Perez L., Lopez-Graniel C., Gonzalez-Enciso A., Gomez-Gonzalez E., Rivera-Rubi L., et al. Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized Phase II study. Int. J. Radiat. Oncol. Biol. Phys. 61 (2005) 817-823
26. Umanzor J., Aguiluz M., Pineda C., Andrade S., and Erazo M. Concurrent chemoradiation in locally advanced cervical carcinoma (LACC): role of a combination of cisplatin, gemcitabine and radiotherapy-A phase II trial. Proc. Am. Soc. Clin. Oncol. 22 (2003) 486
27. Peters G.J., van der Wilt C.L., van Moorsel C.J., Kroep J.R., Bergman A.M., and Ackland S.P. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol. Ther. 87 (2000) 227-253
28. van Moorsel C.J., Pinedo H.M., Veerman G., Vermorken J.B., Postmus P.E., and Peters G.J. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur. J. Cancer 35 (1999) 808-814
29. Crul M., van Waardenburg R.C., Bocxe S., van Eijndhoven M.A., Pluim D., Beijnen J.H., et al. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem. Pharmacol. 65 (2003) 275-282
30. Voigt W., Bulankin A., Muller T., Schoeber C., Grothey A., Hoang-Vu C., et al. Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin. Cancer Res. 6 (2000) 2087-2093
31. Symon Z., Davis M., McGinn C.J., Zalupski M.M., and Lawrence T.S. Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic. Int. J. Radiat. Oncol. Biol. Phys. 53 (2002) 140-145
32. Crul M., Schoemaker N.E., Pluim D., Maliepaard M., Underberg R.W., Schot M., et al. Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 9 (2003) 3526-3533
33. van Moorsel C.J., Kroep J.R., Pinedo H.M., Veerman G., Voorn D.A., Postmus P.E., et al. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann. Oncol. 10 (1999) 441-448
34. Wilkowski R., Thoma M., Duhmke E., Rau H.G., and Heinemann V. Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 768-772
35. Caffo O., Fellin G., Graffer U., Valduga F., Bolner A., Luciani L., et al. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Int. J. Radiat. Oncol. Biol. Phys. 57 (2003) 1310-1316
36. Martenson J.A., Vigliotti A.P., Pitot H.C., Geeraerts L.H., Sargent D.J., Haddock M.G., et al. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 55 (2003) 1305-1310
37. Brunner T.B., Grabenbauer G.G., Klein P., Baum U., Papadopoulos T., Bautz W., et al. Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 55 (2003) 144-153
38. Benasso M., Corvo R., Ponzanelli A., Sanguineti G., Ricci I., Pallestrini E., et al. Alternating gemcitabine and cisplatin with gemcitabine and radiation in stage IV squamous cell carcinoma of the head and neck. Ann. Oncol. 15 (2004) 646-652